Thursday, October 3, 2013
Publication and contact
Mouse model of phosphoinositide
3-kinase catalytic subunit a-polypeptide (PIK3CA; p110a)-mutant, HER2 (EGFR2; ErbB2; neu)+ breast
A mouse model of HER2+
breast cancer with a PIK3CA mutation could be useful for developing
combination therapies to treat the disease. Mice with mammary epithelium-specific
overexpression of human HER2 and a mutant form of PIK3CA had tumors that grew
more aggressively and metastasized more readily than tumors with mammary
epithelium-specific overexpression of HER2 alone. In the mice, the HER2+,
PIK3CA-mutant tumors were resistant to the combination of anti-HER2
antibodies Herceptin trastuzumab and Perjeta pertuzumab. Next
steps include using these mice to test inhibitors of mutant PIK3CA in combination
with HER2 antagonists.
Roche's Genentech Inc. unit markets Herceptin to
treat metastatic breast and gastric cancers and Perjeta to treat metastatic
Published online Oct. 3, 2013
Patent and licensing status
Hanker, A.B. et al.
Proc. Natl. Acad. Sci. USA; published online Aug. 12, 2013;
Contact: Carlos L. Arteaga, Vanderbilt University, Nashville,
Contact: Jean J. Zhao, Harvard Medical School, Boston, Mass.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]